Metformin-associated lactic acidosis

1. Inzucchi, S. E., Bergenstal, R. M., Buse, J. M. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD). Diabetes Care, 2012, 6, p. 1364–1379.

2. Lamanna, C., Monami, M., Marchionni, N., Mannucci, E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes. Metab., 2011, 3, p. 221–228.

3. Pernicova, I., Korbontis, M. Metformin – mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol., 2014, 3, p. 143–156.

4. Glueck, C. J., Fontaine, R. N., Wang, P. et al. Metformin reduces weight, centripetal obesity, insulin, leptin, and low-density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism, 2001, 7, p. 856–861.

5. Salpeter, S. R., Bucklea, N. S., Kahn, J. A., Salpeter, E. E. Meta-analysis: metformin treatment in persons ať risk for diabetes mellitus. Am. J. Med., 2008, 2, p. 149–157.

6. ADVANCE Collaborative Group. Intensive blood control and vascular Outcomes in patients with type 2 diabetes. N. Engl. J. Med., 2008, 24, p. 2560–2572.

7. ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular Outcomes. N. Engl. J. Med., 2011, 9, p. 818–828.

8. Libby, G., Donnelly, L. A., Donnan, P. T. et al. New users of metformin are ať low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care, 2009, 9, p. 1620–1625.

9. Landman, G. W., Kleefstra, N., van Hateren, K. J. et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care, 2010, 2, p. 322–326.

10. Graha, G. G., Punt, J., Arora, M. et al. Clinical pharmacokine­tics of metformin. Clin. Pharmacokinet., 2011, 2, p. 81–98.

11. Duong, J. K., Furlong, T. J., Roberts, D. M. et al. The role of metformin in metformin-associated lactic acidosis (MALA): case series and formulation of a model of pathogenesis. Drug Saf., 2013, 9, p. 733–746.

12. de Jager, J., Kooy, A., Lehert, P. et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 2010, 340, p. 2181–2187.

13. Andrzejewski, S., Gravel, S-P., Pollak, M., St-Pierre, J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab., 2014, 2.

14. Wheaton, W. W., Weinberg, S. E., Chandel, N. S. et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumourgenesis. eLife, 2014, 3.

15. Bridges, H. R., Jones, A. J., Pollak, M. N., Hirst, J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J, 2014, 3, p. 475–487.

16. Vecchio, S., Giampreti, A., Petrolini, V. M. et al. Metformin accumulation: lactic acidosis and high plasmatic metformin levels in retrospective case series of 66 patients on chronic therapy. Clin. Toxicol., 2014, 2, p. 129–135.

17. Salpeter, S., Greyber, E., Pasternak, G., Salpeter, E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2006, 1.

18. Salpeter, S., Greyber, E., Pasternak, G., Salpeter, E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev, 2010, 4.

19. Chang, C. T., Chen, Y. C., Fang, J. T., Huang, C. C. High anion gap metabolic acidosis in suicide: don’t forget metformin intoxication – two patients‘ experiences. Ren Fail, 2012, 5, p. 671–675.

20. Lalau, J. D., Lacroix, C., Compagnon, P. et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care, 1995, 18, 6, p. 779–784.

21. Lalau, J. D., Race, J. M. Lactic acidosis in metformin-treated patients. Prognostic value of arterial lactate levels and plasma metformin concentration. Drug Saf, 1999, 4, p. 377–384.

22. DeFronzo, R., Fleming, G. A., Chen, K., Bicsak, T. A. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism, 2016, 2, p. 20–29.

23. Kirpichnikov, D., McFarlane, S. I., Sowers, J. R. Metformin: an update. Ann. Intern. Med., 2002, 1, p. 25–33.

24. Seidowsky, A., Nseir, S., Houdret, N., Fourrier, F. Metformin--associated lactic acidosis: a prognostic and therapeutic study. Crit. Care Med., 2009, 7, p. 2191–2196.

25. Friesecke, S., Abel, P., Roser, M., Felix, S. B., Runge, S. Outcome of severe lactic acidosis associated with metformin accumulation. Crit. Care, 2010, 6, p. 226.

26. Radej, J., Matejovic, M., Krouzecky, A. et al. How severe acidosis can a human survive? Successful hemofiltration use. Dial. Transplant., 2007, 11, p. 608–611.

27. Hoste, E. A., Dhondt, A. Clinical review: use a renal replacement therapies in special groups of ICU patients. Crit. Care, 2012, 1, p. 201.

28. Calello, D. P., Liu, K. D., Wiegand, T. J. et al. Extracorporeal treatment for metformin poisoning: systematic review and re­commendations from the extracorporeal treatments in poisoning workgroup. Crit. Care Med., 2015, 8, p. 1716–1730.

29. Ronco, C., Ricci, Z., DeBacker, D et al. Renal replacement therapy in acute kidney injury: controversy and consensus. Crit. Care, 2015, 1, p. 146–156

30. Vinsonneau, C., Allain-Launay, E., Blayau, C. et al. Renal replacement therapy in adult and pediatric intensive care: recommendations by an expert panel from the SRLF with the SFAR, GFRUP and SFD. Ann. Intensive Care, 2015, 1, p. 58.

31. Bai, M., Zhou, M., He, L. et al. Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med., 2015, 12, p. 2098–2110.